Introduction
Alzheimer's disease (AD) is characterized by progressive dementia and by pathological fibrillar deposits in the brain. Neurofibrillary tangles composed of hyperphosphorylated tau and
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Background: Amyloid-␤ (A␤) accumulates in plaques and as cerebral amyloid angiopathy (CAA) in the brains of both Alzheimer's disease (AD) patients and transgenic A␤PPswe/tg2576 (tg2576) mice. Increasingly, evidence in humans and mice shows this process to be modulated by apolipoprotein E (apoE). Materia fls and Methods: To explore this relationship, we measured apoE and A␤ levels in brains of tg2576 mice and controls at intervals between 2 and 20 months. In addition, A␤ concentrations in plasma and muscle of these animals were also quantified. Results: Quite strikingly, we found that the amount of tg2576 mice brain apoE was elevated by an average of 45%, relative to the control mice from 2 months on. The level of brain apoE soared after 14 months to almost 60% greater than the level found in control mice. A␤ concentrations in brains before 9 months were less than 2 ng/mg of protein, but by 14 months concentrations rose to 8.7 ng/mg, and by 20 months to 47 ng/mg. In plasma, we noted that the levels of A␤ in tg2576 mice declined from above 30 ng/ml prior to 12 months to 14 ng/ml by 14 months. Histology showed that A␤ plaques and CAA began to be discernible in the tg2576 mice at about 9 and 20 months of age, respectively. Conclusions: ApoE was immunocytochemically detected in neuritic plaques that were positive for thioflavine-S. We suggest that the elevation of brain apoE in tg2576 mice participates in an age-related dysregulation of A␤ clearance and signals the start of A␤ sequestration during the time of cognitive dysfunction.
glycolipids accumulate within neurons (1, 2) . Amyloid-␤ (A␤) peptides, primarily as A␤1-40 and A␤1-42, accumulate in fibrillar and nonfibrillar forms as senile plaques in the extracellular spaces of the brain parenchyma and in the arterial walls, both within the brain and in the leptomeninges as cerebral amyloid angiopathy (CAA; [3] [4] [5] [6] . The contribution of cerebral vasculature pathology to the dementia of AD in relation to CAA, atherosclerosis and arteriosclerosis, and embolic-ischemic brain damage is increasingly recognized (7).
Amyloid-␤, a natural product of A␤ precursor protein (A␤PP) metabolism, begins to accumulate in the brain at around 50 years of age and shows a very substantial rise in patients with AD (8) . The molecular basis for this A␤ sequestration and deposition remains obscure. However, recent studies implicate apolipoprotein E (apoE) in this process. ApoE is a protein involved in the transport of cholesterol and triglycerides (9) . In humans, there are three isoforms of apoE (apoE2, E3 and E4), which differ by only one or two amino acids. Numerous studies show that apoE4 status increases the risk for AD or accelerates its age of onset (10, 11) . ApoE4 dosedependency increases the levels of A␤ peptide in aging and AD brains, in both parenchyma and the cerebral vasculature (12, 13) .
In light of the above findings, we sought to determine the status of apoE levels in the brains of tg2576 A␤PP mice, in conjunction with those levels of A␤ found centrally in the brain and peripherally in the plasma. In addition, the levels of cholesterol, ␣1-antichymotrypsin, Ͱ-synuclein and C1q in the brains and A␤ in muscle of tg2576 mice and non-tg mice were measured.
Materials and Methods

Transgenic Mice
The transgenic A␤PPswe mice from the 2576 line (C57B6/SJL) used in the present study were developed by Hsiao et al. (14) . These mice contain the human A␤PP695, with the double mutation Lys670→Asn, Met671→Leu (A␤PP 770 numbering), which was inserted into a hamster prion protein (PrP) cosmid vector. The mice brains used in the present study were provided by M. Mullan Roskamp Institute, University of South Florida, Tampa FL. Previous histopathological analysis showed that between the young (2-8 months) and the old (11-13 months) tg2576 mice there was a 14-fold increase in the amount of A␤42 in the brain and a 5-fold increase in A␤40 (14) . The tg2576 mice exhibited learning and memory impairment at 9-10 months of age.
Tissue Preparation, Chromatography, and A␤ Quantitation
A total of 18 tg2576 and 18 control mice were involved in this study. The mice were terminated at 2, 4, 9, 12, 14, and 20 months of age. In both groups, each age was represented by three mice. Blood was immediately collected by venipuncture from the brachiocephalic vein using a 1 ml syringe primed with 30 l of K 3 EDTA (4.5 mg) and centrifuged to separate the plasma from the cells. The right hemisphere, pectoralis major and sternomastoid muscles were removed and immediately frozen at Ϫ70ЊC until the moment of processing. For immunostaining, the left hemispheres were fixed in 4% paraformaldehyde (Fluka Chemie AG, Bucks, Switzerland) for 48 hr and stored in phosphate-buffered saline (PBS) at 4ЊC.
The right cerebral cortex (120-180 mg) was homogenized in 5 volumes of 20 mM Tris-HCl (Sigma Chemical Company, St. Louis, MO), pH 7.5, and a sample of 5 l was diluted 1000 fold to measure total protein concentration using the Micro BCA protein assay kit (Pierce, Rockford, IL). 50 l of the brain homogenate was set aside for cholesterol measurements. The remaining homogenate was immediately centrifuged at 500,000 ϫ g for 15 min at 5ЊC. The supernatant was used for the determination of soluble A␤. For the determination of insoluble A␤, the pellet was homogenized in 1 ml of 98% glass-distilled formic acid (GDFA) and centrifuged at 500,000 ϫ g for 20 min at 5ЊC. From each mouse, 200 mg of skeletal muscle was finely minced, directly homogenized in 5 ml of GDFA and centrifuged at 200,000 ϫ g for 30 min at 5ЊC. 500 l harvested from the middle volume of the clear acid supernatant, from either brain or muscle, was loaded onto a Superose 12 column (HR 10 ϫ 300 mm, Amersham-Pharmacia, Piscataway, NJ). To separate the A␤ peptides from other circulating molecules, 50 l of plasma was diluted with 450 l of 98% GDFA and applied onto the Superose 12 column. All chromatographic separations were carried out using a AmershamPharmacia fast performance liquid chromatography (FPLC) apparatus, developed in 80% GDFA, at a flow rate of 15 ml/hour at room temperature, and monitored at 280 nm. The chromatographic fractions corresponding to the 4.0-4.5 kDa (2 ml) were pooled and, after addition of 20 l of 10% betaine (Sigma Chemical Co.), the acid was totally removed by vacuum centrifugation.
FPLC separated 4.0 to 4.5 kDa A␤-containing-fractions from plasma, brain, and muscle. A␤ levels in these fractions were determined using the europium immunoassay (EuIA) (Wallac Inc., Gaithersburg, MD) as described in detail elsewhere (15) . Polyclonal antibodies, R163 and R165 (provided by P. Mehta, New York Institute for Basic Research and Mental Disabilities, Staten Island, NY), raised against the C-terminal sequence of A␤ residues 34-40 and 36-42, respectively (16), were used as capture antibodies. The monoclonal antibody, 4G8 (Senetec, Maryland Heights, MO), against A␤ sequence residues 17-24, was labeled with europium (Eu) and used as a reporter antibody. In an independent experiment, the monoclonal antibody 6E10 (Senetec), against A␤ residues 1-16, was used as a capture antibody. To confirm the reliability of our data, a second set of polyclonal antibodies, R209 and R226, raised against A␤ residues 34-40 and 36-42, respectively, kindly provided by P. Mehta was also used as capture antibodies.
Western Blot Analysis and Protein Quantification
Western blot analysis was used to determine protein levels in the brain. For the detection of A␤PP, monoclonal antibody 22C11 (BoehringerMannheim, Indianapolis, IN) was used as the primary antibody. For apoE, we used a goat anti-rat polyclonal antibody, kindly provided by C. L. Bisgaier (Esperion Therapeutics, Ann Arbor, MI) and P. J. Dolphin (Dalhousie University, Halifax, NS, Canada). The antibody was raised against the rat apoE that was purified by the method of Holmquist and Carlson (17) and its purity was assessed by SDS-PAGE (18) . The specificity of this antibody was verified by two-dimensional crossed immunoelectrophoresis (19) . For C1q and ␣1-antichymotrypsin, the antisera were obtained from Dako (Glostrup, Denmark). For Ͱ-synuclein quantitation, the antibody was kindly donated by Eliezer Masliah (University of California at San Diego, San Diego, CA). All Western blots were developed with the Supersignal Chemiluminescent Substrates (Pierce) and the relative intensities of the bands were measured on a scanning ChemiImager (Alpha Innotech Corp., San Leandro, CA).
Brain Cholesterol Quantitation
Cholesterol levels in brain were estimated using the modified Folch technique for lipid extraction (20) . Briefly, to each 50 l of initial brain homogenate, 10 g of 4-cholesten-3-one (ICN Biomedicals Inc., Aurora, OH) was added as an internal standard for high performance liquid chromatography (HPLC). The sample was homogenized in 250 l of chloroform: methanol (2 : 1, v/v) and filtered through Whatman No. 1 filter paper. Another 250 l of chloroform:methanol mixture were used to reextract the residue. Water (100 l) was added to the filtrates and the organic layer was collected after centrifugation at 12,000 ϫ g for 10 min. The lipid extracts were completely dried under a fine nitrogen stream and then dissolved in 500 l of 5% 2-propanol:hexane (volume per volume; v/v). The cholesterol was purified by HPLC (Thermo Separation Products, Freemont, CA) on a silica normal phase column (Zorbax SIL, 4.6 ϫ 250 mm, 5 m) at a flow rate of 1 ml per min. The relative absorbance values at 208 nm between the internal standard and the cholesterol were considered in the final calculation of brain cholesterol.
Immunocytochemistry
The paraformaldehyde-fixed left hemisphere was sectioned at 40 m and stained with antibodies 4G8 and 6E10 (Senetec) for A␤ or anti-apoE antibody (19) . Sections were incubated in primary antibodies at 1 : 1000 overnight at 4ЊC, followed by a biotinylated secondary antibody (1 : 2000) and an avidinbiotin-peroxidase (ABC, Vector Laboratories, Burlingame, CA) using 3,3Ј-diaminobenzidine as the substrate. Control sections were treated identically, except for the omission or preabsorption of the primary antibody with 100 g/ml synthetic A␤ 1-40. A section of frontal cortex from a AD case was used as a positive control.
Statistical Analyses
To study the within-group relationships, regression models (linear or nonlinear) were separately applied to the tg2576 mice or non-tg mice. When group and age were incorporated as independent variables, a 2-way factorial analysis of variance (ANOVA) was used. Post-hoc multiple comparison (Fisher's LSD) was employed to analyze individual significant effects.
Results
Apolipoprotein E Levels in Brain
The levels of apolipoprotein E in the brain of tg2576 mice were higher than those observed in the non-tg mice (F ϭ 24.63; p Ͻ 0.001). In addition, in the former, there was a steady increase in apoE with age (Fig. 1A) . During the first 12 months, this elevation was relatively constant in the tg2576 mice, with levels 30-34% greater than those in the non-tg mice. However, this difference became more pronounced at 14 and 20 months of age (53% and 57%, respectively), reaching statistical significance at these ages.
Since apoE is a cholesterol carrier, we then sought to observe the changes of brain cholesterol. Our results demonstrated that the increase in brain apoE levels was not a reflection of increased brain cholesterol. The levels of cholesterol in the brains of tg2576 and non-tg mice progressively increased with age (F ϭ 5.73; p ϭ 0.001), but no statistical difference was found between the two groups (F ϭ 0.42; p Ͼ 0.5; Fig. 1B) .
As expected, the A␤PP values were almost ten times higher in the brains of tg2576 mice (Mean relative optical density (OD) units ϭ 16.9, range: 14-20) than in the non-tg mice The levels of plasma A␤ peptides, quantified by antibody 6E10 (A␤1-40/42). In both instances (C and D), the total plasma A␤ was significantly increased (*, p Ͻ 0.05) in the tg2576 mice at the ages of 9 and 12 months, relative to controls. (E) and (F) The amounts of water-insoluble and water-soluble A␤ peptides, respectively, in the tg2576 and control mice brains. After 12 months of age, the quantities of total A␤ in the tg2576 mice brain increased in a quasi-exponential mode.
(Mean ϭ 1.7, range: 0.27-4.5). However, these levels of A␤PP remained stable throughout the life of the tg2576 animals (Fig. 2) . The elevation of apoE was unique among the other brain proteins that we studied. No statistically significant differences were found in the amounts of C1q, Ͱ1-antichymotrypsin and Ͱ-synuclein in the brains of tg2576 mice and non-tg mice at all ages (data not shown).
A␤ Levels in Plasma
There was a significant increase with age in the levels of total A␤, defined as the sum of A␤40 and A␤42, in the plasma of the tg2576 mice from 2 months to 12 months (r ϭ 0.678, p ϭ 0.022; Fig. 1C) . As age advanced, tg2576 mice showed a sharp decrease in the plasma A␤ levels at 14 months (p Ͻ 0.05) followed by a moderate increase by 20 months. During this period, the A␤42 was, on the average, about three times more abundant than A␤40 in the plasma of tg2576 mice. Unlike the tg mice, the A␤ levels in the plasma of the non-tg littermates increased slowly (r ϭ 0.507; p ϭ 0.032) throughout the entire experimental period (Fig. 1C) . In the non-tg mice, the overall average ratio of A␤42 over A␤40 was 2 : 1. A similar timedependent trend was observed in the tg2576 mice when the 6E10 and 4G8 antibodies were used to measure only the human form of total A␤ in plasma (Fig. 1D) . As expected, the nontg mice demonstrated basal levels of A␤ in plasma with the 6E10 antibody, since it did not recognize the sequence of amino acids 1-16 of the mouse A␤ peptide (Fig. 1D) .
In contrast to plasma, there was no statistically significant difference between the levels of A␤ in skeletal muscle of tg2576 and non-tg mice at the ages investigated ( f ϭ 0.755; p Ͼ 0.5). The average value for total A␤ in the tg2576 mice was 65 ng/g of muscle (range: 31-104 ng/g of muscle) and for the non-tg mice was 100 ng/g of muscle (range: 19-178 ng/g).
A␤ Levels in Brain
The drop in plasma A␤ levels in tg2576 mice was inversely correlated with an exponential increase in the brain A␤ levels. Until 9 months of age, the levels of soluble and insoluble A␤40 and A␤42 in the brain remained below 2 ng/mg of protein in both the tg2576 and non-tg mice (Fig. 1E and 1F) . By 14 months of age, the total A␤ in the tg2576 mice had reached 8.7 ng/mg of protein and, by 20 months, it was 47 ng/mg of protein (Fig. 1E) . In the brains of the 20-monthold tg2576 mice, A␤42 was five times more abundant than A␤40. Non-tg mice showed no substantial change in the levels of A␤ in the brain with age, remaining below 0.7 ng/mg of protein from 2 to 20 months of age (Fig. 1E) .
Interestingly, when the amounts of total brain A␤ were plotted against the levels of brain apoE in the tg2576 mice, a significant correlation was found (r 2 ϭ 0.545; p ϭ 0.006). However, since the amounts of total brain A␤ in tg2576 mice displayed a second-order hyperbolic distribution (Fig. 1E and 1F) , the log values of the total brain A␤ levels were plotted against apoE concentrations. Using this approach, a positive correlation was also demonstrated (r 2 ϭ 0.349; p ϭ 0.043).
Neuropathology
At all ages studied, there was a total absence of amyloid deposits in the non-tg mice. In contrast, in the tg2576 mice, sparse diffuse plaques and few small punctuated amyloid cores positive for thioflavine S were evident at 12 months of age in both the hippocampus and the cortex. By 14 months, the number of star-like amyloid plaques stained by thioflavine S and Campbell-Switzer histochemistry, as well as diffuse amyloid deposits, were numerous in both regions of the brain. In the 20-month-old tg2576 mice, there were abundant and larger amyloid plaques with dense cores, which in many instances, closely assembled and occasionally coalesced ( Fig. 3A and  B) . Also at 20 months of age, cerebrovascular amyloid deposits were visible for the first time in larger vessels, especially in the hippocampal fissure. Amyloid plaques positive for thioflavine S were also intensely stained for apoE immunocytochemistry (Fig. 3C ).
Discussion
Studies in A␤PP tg2576 mice suggested that apoE may play a paradoxical role in the clearance of A␤ from brain. Decreased A␤ levels caused by maintaining A␤PP mice on a high cholesterol diet required the presence of apoE (21) . In contrast, Bales and colleagues (22, 23) showed that the deposition, not the clearance, of A␤ in the brains of aging PDAPP tg mice was apoE dependent. In an effort to reconcile these seemingly contradictory roles, we followed the natural history of A␤ and apoE levels in the brains of aging A␤PP tg2576 mice. To our surprise, the levels of apoE and A␤ increased in parallel with age, at the expense of decreasing A␤ levels in plasma from these animals. This finding implied reduced clearance of the peptide from the brain. The elevation of apoE was unique among the brain proteins that we studied. Moreover, the change in apoE occurred without a significant change in brain cholesterol. Thus, our results favor a role for apoE in the sequestration of A␤ in the brains of aging tg2576 mice. Considerable importance has been attached to apoE status in AD, since individuals who are apoE4 are at increased risk for this dementia (24, 25) . However, the mechanism or mechanisms responsible for the apoE4 effect in AD must be elucidated. In light of our present results, it is provocative to note that human apoE4 is analogous to the apoE found in mice (26) . A consistent consequence of carrying the apoE ⑀4 gene is an increased amyloid burden in brain and cerebral vasculature. In AD, apoE4 is linked to increased numbers of amyloid plaques in brain parenchyma, as well as more abundant CAA (12, 13) . A cross-sectional study of over 200 brains from nondemented elderly subjects reveals that individuals bearing the gene for apoE4 have increased diffuse deposits of A␤42, in addition to a greater incidence of CAA (27) . Parenthetically, these diffuse deposits are common in subjects with mild cognitive impairment (MCI), a condition considered prodromal to the clinical onset of AD (28, 29) . A similar association between apoE4 status and amyloid deposition also was seen after traumatic brain injury resulting from accidents (30) or boxing (31) . The importance of apoE4 to amyloid deposition was underscored by the work of Carter et al. (32) who showed that tg2576 mice bearing human apoE4 produced more amyloid plaques than those mice without apoE or with human apoE3 (32) . This latter result, in particular, supports the notion that apoE4 participates directly in the deposition of A␤ in brain Numerous studies have examined the possible A␤ and apoE interactions responsible for the apolipoprotein-associated changes in AD. In general, these studies show that the interactions of A␤ with apoE are isoform-dependent when the apolipoprotein is lipidated. Several laboratories report that human apoE4 in a lipid complex binds less well to A␤ than either apoE3 and apoE2 (33) (34) (35) . Genetically substituting cysteine for arginine at position 158 is sufficient to make apoE4 behave like apoE3, with respect to A␤ binding (36) . Cell culture studies report conflicting effects of apoE4 on the clearance of A␤. ApoE4 stimulates the uptake of A␤ by primary cultures of rat hippocampal neurons (37) , but inhibits A␤ uptake by Chinese hamster ovary cells (38) .
A number of facets of apoE4's functions or properties might lead to increased A␤ in the central nervous system (CNS). Some, but not all, studies indicate that apoE4 increases the fibrillogenesis of A␤, thereby, promoting its deposition (39) (40) (41) (42) . The relative inability of apoE4 to bind A␤ compared with the other apoE isoforms (33,36) might also hinder A␤ clearance (38, 43) . The overexpression of transforming growth factor-␤ (TGF-␤) in brain, which increases apoE expression along with that of heparan sulfate proteoglycan (HSPG), promotes amyloid deposition in the cerebral vasculature of A␤PP tg mice (44) . Thus, it is also possible that apoE4 provides an essential component for the development of an extracellular milieu favoring A␤ deposition.
It is well recognized that apoE binds A␤ and acts as a transporter for this molecule in both the CNS and in the circulation (43, 45, 46) . Lipidated apoE also interacts with HSPG prior to endocytosis by the low density lipoprotein (LDL) receptor and LDL receptor-related protein (LRP; 47). Chemical and immunocytochemical analyses have demonstrated the presence of HSPG, apoE and A␤ peptide in both neuritic plaques and CAA (48, 49) . When HSPG levels are experimentally up-regulated, A␤ is profusely deposited in the vascular walls (44) . An even more intriguing observation is that the presence of apoE increases the sulfation of glycosaminoglycans (GAG; 50). Furthermore, the moieties of GAG are relevant to A␤ aggregation, since they can enhance the rate of fibrillogenesis (51) . These data suggest that apoE in AD has significant pleiotropic effects: (1) as an A␤ carrier molecule, the expression of apoE responds to A␤ concentrations and is upregulated when the A␤ levels increase in the brain; (2) elevations in apoE may promote sharply increased GAG sulfation; and (3) because both apoE and A␤ have a high affinity for GAG, the enhanced GAG sulfation may promote A␤ fibrillogenesis. Future experiments will resolve which of the possible mechanistic roles of apoE is critical to the deposition of A␤ in the brains of A␤PP transgenic mice.
It is remarkable that the observed rise of A␤ in the plasma peaks at a time coinciding with cognitive decline in tg2576 mice. Although some learning impairments can be detected in the tg2576 mice as early as 3 months of age, it is only after 9 months that impairment of spatial memory, measured by the Morris water maze test, reaches statistical significance (14, 52) . Oddly, a somewhat similar pattern is observed in people with MCI. Mayeux and his colleagues (53) reported recently that MCI patients had higher plasma levels of A␤ than normal controls. The elevated levels of plasma A␤ are associated with an increased risk for AD. Yet, people with MCI fail to manifest the robust histopathological hallmarks, plaques and tangles, found in AD brains (28) . Instead, MCI individuals manifest diffuse plaques (28, 29) and some hippocampal atrophy (54), in conjunction with their cognitive decline. Interestingly, the presence of plaques and hippocampal atrophy in nondemented or cognitively impaired individuals is often associated with cardiovascular disease (55, 56) .
One must wonder if the rise in plasma A␤ signals the beginning of a neurodegenerative process that ultimately leads to AD. Based on our current results in tg2576 mice, it is conceivable that plasma A␤ is derived from the brain and transported into the periphery. Failure to maintain this clearance could result in the accumulation of A␤ in the form of fibrillar amyloid plaques. However, implicit in this conjecture is the possibility that it is the pathology leading to the failure to clear A␤, rather than the accumulation of A␤ itself, that is responsible for the pathological and behavioral changes of AD. From this perspective, the A␤PP transgenic mice, although not recapitulating the full spectrum of AD neuropathology, might reflect both central and peripheral changes indicative of the incipient stages of the dementia. If true, then the A␤PP tg mice may be invaluable for elucidating the biochemical, physiological, and morphological underpinnings of Alzheimer dementia in statu nascendi. Thus, detailed molecular characterization of these murine models might provide indica-tions of the optimal therapeutic prevention of age-related dementia. In light of our results, it will be of particular interest to determine precisely the role that apoE plays in the clearance or accumulation of A␤ in the brains of aging tg2576 mice.
